Oral Delivery of Teriparatide Using a Nanoemulsion System: Design, in Vitro and in Vivo Evaluation

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 2020 Apr 8

PMID 32253527

Citations 5

Authors

Bashar M Altaani

Ammar M Almaaytah

Suha Dadou

Khouloud Alkhamis

Mousa H Daradka

Wael Hananeh

Affiliations

Soon will be listed here.

Abstract

Purpose: Investigate the possibility of delivering teriparatide orally using nanoemulsion.

Method: Teriparatide was allowed to interact with chitosan in the presence of HPβCD.The formed polyelectrolyte complex (PEC) was characterized by DSC, FTIR, DLS and for entrapment efficiency. PEC was the incorporated in an oil phase consisting of Oleic Acid, Labrasol and Plurol Oleique to form a nanoemulsion. This preparation was characterized for refractive index, viscosity, pH, conductivity, particle size, and morphology.Bioavailability of the preparation was evaluated using rabbits against SC injection. The efficacy of the formula was tested using ovariectomized rats (an osteoporosis animal model) and mechanical and histological tests were conducted on their bones. The stability of the preparation was evaluated by storing samples at 4 C, 25 C and 40 C for three months.

Results: PEC testing demonstrate a complex formation with particle size of 208 nm, zeta potential of +17 mV and entrapment efficiency of 49%. For the nanoemulsion, the results demonstrate the formation of a nano-sized dispersed system (108 nm) with a drug loading of 98% and a percent protection of 90% and 71% in SGF and SIF respectively. Bioavailability results showed a sustained release profile was achieved following the oral formulation administration. Efficacy studies showed improvement in the strength, thickness and connectivity of bones. Short-term stability study demostrated that the nanoemulsion is mostly stable at 4 C.

Conclusion: These findings demonstrate the ability of delivering Teriparatide orally using oleic acid based dispersion in combination with chitosan PEC.

Citing Articles

Mechanistic advances in osteoporosis and anti-osteoporosis therapies.

Wang H, Luo Y, Wang H, Li F, Yu F, Ye L MedComm (2020). 2023; 4(3):e244.

PMID: 37188325 PMC: 10175743. DOI: 10.1002/mco2.244.

Anabolic Peptide-Enriched Stealth Nanoliposomes for Effective Anti-Osteoporotic Therapy.

Salave S, Rana D, Kumar H, Kommineni N, Benival D Pharmaceutics. 2022; 14(11).

PMID: 36365235 PMC: 9697760. DOI: 10.3390/pharmaceutics14112417.

Parathyroid Hormone 1 Receptor Signaling in Dental Mesenchymal Stem Cells: Basic and Clinical Implications.

Lyu P, Li B, Li P, Bi R, Cui C, Zhao Z Front Cell Dev Biol. 2021; 9:654715.

PMID: 34760881 PMC: 8573197. DOI: 10.3389/fcell.2021.654715.

The Effect of Space Travel on Bone Metabolism: Considerations on Today's Major Challenges and Advances in Pharmacology.

Genah S, Monici M, Morbidelli L Int J Mol Sci. 2021; 22(9).

PMID: 33925533 PMC: 8123809. DOI: 10.3390/ijms22094585.

MANAGEMENT OF ENDOCRINE DISEASE: Postsurgical hypoparathyroidism: current treatments and future prospects for parathyroid allotransplantation.

Mihai R, Thakker R Eur J Endocrinol. 2021; 184(5):R165-R175.

PMID: 33599211 PMC: 8052514. DOI: 10.1530/EJE-20-1367.

References

Turner A . Animal models of osteoporosis--necessity and limitations. Eur Cell Mater. 2003; 1:66-81. DOI: 10.22203/ecm.v001a08. View

Narayanan D, Anitha A, Jayakumar R, Nair S, Chennazhi K . Synthesis, characterization and preliminary in vitro evaluation of PTH 1-34 loaded chitosan nanoparticles for osteoporosis. J Biomed Nanotechnol. 2012; 8(1):98-106. DOI: 10.1166/jbn.2012.1367. View

Hoegh-Andersen P, Tanko L, Andersen T, Lundberg C, Mo J, Heegaard A . Ovariectomized rats as a model of postmenopausal osteoarthritis: validation and application. Arthritis Res Ther. 2004; 6(2):R169-80. PMC: 400436. DOI: 10.1186/ar1152. View

Yu Z, Rogers T, Hu J, Johnston K, Williams 3rd R . Preparation and characterization of microparticles containing peptide produced by a novel process: spray freezing into liquid. Eur J Pharm Biopharm. 2002; 54(2):221-8. DOI: 10.1016/s0939-6411(02)00050-4. View

Stolnik S, Shakesheff K . Formulations for delivery of therapeutic proteins. Biotechnol Lett. 2008; 31(1):1-11. DOI: 10.1007/s10529-008-9834-y. View

Djordjevic L, Primorac M, Stupar M, Krajisnik D . Characterization of caprylocaproyl macrogolglycerides based microemulsion drug delivery vehicles for an amphiphilic drug. Int J Pharm. 2004; 271(1-2):11-9. DOI: 10.1016/j.ijpharm.2003.10.037. View

Agnihotri S, Mallikarjuna N, Aminabhavi T . Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J Control Release. 2004; 100(1):5-28. DOI: 10.1016/j.jconrel.2004.08.010. View

Komrakova M, Stuermer E, Werner C, Wicke M, Kolios L, Sehmisch S . Effect of human parathyroid hormone hPTH (1-34) applied at different regimes on fracture healing and muscle in ovariectomized and healthy rats. Bone. 2010; 47(3):480-92. DOI: 10.1016/j.bone.2010.05.013. View

Washimi Y, Ito M, Morishima Y, Taguma K, Ojima Y, Uzawa T . Effect of combined humanPTH(1-34) and calcitonin treatment in ovariectomized rats. Bone. 2007; 41(5):786-93. DOI: 10.1016/j.bone.2007.06.019. View

10.

Sajeesh S, Sharma C . Cyclodextrin-insulin complex encapsulated polymethacrylic acid based nanoparticles for oral insulin delivery. Int J Pharm. 2006; 325(1-2):147-54. DOI: 10.1016/j.ijpharm.2006.06.019. View

11.

Guo L, Ma E, Zhao H, Long Y, Zheng C, Duan M . Preliminary evaluation of a novel oral delivery system for rhPTH1-34: in vitro and in vivo. Int J Pharm. 2011; 420(1):172-9. DOI: 10.1016/j.ijpharm.2011.08.029. View

12.

Theiszova M, Jantova S, Dragunova J, Grznarova P, Palou M . Comparison the cytotoxicity of hydroxyapatite measured by direct cell counting and MTT test in murine fibroblast NIH-3T3 cells. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2006; 149(2):393-6. View

13.

Bartolozzi E . The natural approach to osteoporosis. Clin Cases Miner Bone Metab. 2015; 12(2):111-5. PMC: 4625766. DOI: 10.11138/ccmbm/2015.12.2.111. View

14.

Choonara B, Choonara Y, Kumar P, Bijukumar D, du Toit L, Pillay V . A review of advanced oral drug delivery technologies facilitating the protection and absorption of protein and peptide molecules. Biotechnol Adv. 2014; 32(7):1269-1282. DOI: 10.1016/j.biotechadv.2014.07.006. View

15.

Kim D, Jeong Y, Choi C, Roh S, Kang S, Jang M . Retinol-encapsulated low molecular water-soluble chitosan nanoparticles. Int J Pharm. 2006; 319(1-2):130-8. DOI: 10.1016/j.ijpharm.2006.03.040. View

16.

Berger J, Reist M, Mayer J, Felt O, Gurny R . Structure and interactions in chitosan hydrogels formed by complexation or aggregation for biomedical applications. Eur J Pharm Biopharm. 2004; 57(1):35-52. DOI: 10.1016/s0939-6411(03)00160-7. View

17.

Quattrocchi E, Kourlas H . Teriparatide: a review. Clin Ther. 2004; 26(6):841-54. DOI: 10.1016/s0149-2918(04)90128-2. View

18.

Khalil S, El-Feky G, El-Banna S, Khalil W . Preparation and evaluation of warfarin-β-cyclodextrin loaded chitosan nanoparticles for transdermal delivery. Carbohydr Polym. 2012; 90(3):1244-53. DOI: 10.1016/j.carbpol.2012.06.056. View

19.

Carrier R, Miller L, Ahmed I . The utility of cyclodextrins for enhancing oral bioavailability. J Control Release. 2007; 123(2):78-99. DOI: 10.1016/j.jconrel.2007.07.018. View

20.

Koga K, Kusawake Y, Ito Y, Sugioka N, Shibata N, Takada K . Enhancing mechanism of Labrasol on intestinal membrane permeability of the hydrophilic drug gentamicin sulfate. Eur J Pharm Biopharm. 2006; 64(1):82-91. DOI: 10.1016/j.ejpb.2006.03.011. View